RE:RE:RE:Durability, Durability, DurabilityConsider also that ONCY's pelareorep can work to enhance the effectiveness of small molecule inhibitors like PARP inhibitors which target the glycoprotein CD39 (PARP enzyme) that catayzes adenosine tri-phosphate (ATP) into adenosine. Adenosine is a significant immunosuppressive neucloside of the tumor microenvironment (TME) as outlined in an earlier post.
Pfizer's PARP inhibitor's are Ibrance, whose patent will expire in 4 years, and Talzenna (talazoparib), whose patent will expire in October 2029. [ Approval with pelareorep would add 12 years of FDA market exclusivity to both PARP drugs from the date of marketing approval ]
As also pointed out, ONCY's pelareorep down-regulates adenosine, and therefore blocks the immunosuppressive activity that adenosine tends to exert on the TME, as referenced above, with the result being that pelareorep converts an otherwise hostile immunosuppressive TME into one that is conducive to immune checkpoint inhibitors, like Pfizer/Merck KGaA's Bavencio or Roche's Tecentriq, as examples.